Oncogenic PIK3CA mutations in lobular breast cancer progression

Genes Chromosomes and Cancer

Volumn 52, Issue 1, 2013, Pages 69-80

  Christgen, Matthias ^a   Noskowicz, Monika ^a   Schipper, Elisa ^a   Christgen, Henriette ^a   Heil, Charlotte ^a   Krech, Till ^a   Länger, Florian ^a   Kreipe, Hans ^a   Lehmann, Ulrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN KINASE B; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LOBULAR BREAST CANCER; ONCOGENE; PHOSPHATIDYLINOSITOL 3 KINASE CA GENE; PRIORITY JOURNAL; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; FORMALDEHYDE; HISTOCYTOCHEMISTRY; HUMANS; MUTATION; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASES; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84869870316     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22007     Document Type: Article

References (51)

1. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. 2004. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
2. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. 2007. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13: 6064-6069.
3. Bertucci F, Orsetti B, Negre V, Finetti P, Rouge C, Ahomadegbe JC, Bibeau F, Mathieu MC, Treilleux I, Jacquemier J, Ursule L, Martinec A, Wang Q, Benard J, Puisieux A, Birnbaum D, Theillet C. 2008. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27: 5359-5372.
4. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. 1995. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. Embo J 14: 6107-6115.
5. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A, Wang Q. 2012. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 132: 29-39.
6. Bozhanov SS, Angelova SG, Krasteva ME, Markov TL, Christova SL, Gavrilov IG, Georgieva EI. 2010. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol 136: 1657-1669.
7. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A. 2006. PIK3CA mutation and histological type in breast carcinoma: High frequency of mutations in lobular carcinoma. J Pathol 208: 350-355.
8. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. 2004. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
9. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
10. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. 2008. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
11. Christgen M, Bruchhardt H, Hadamitzky C, Rudolph C, Steinemann D, Gadzicki D, Hasemeier B, Romermann D, Focken T, Krech T, Ballmaier M, Schlegelberger B, Kreipe H, Lehmann U. 2009. Comprehensive genetic and functional characterization of IPH-926: A novel CDH1-null tumour cell line from human lobular breast cancer. J Pathol 217: 620-632.
12. Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G. 2012. Outcome of special types of luminal breast cancer. Ann Oncol 23: 1428-1436.
13. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. 2002. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 87: 1105-1111.
14. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN. 2005. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23: 41-48.
15. Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, Clarke C, Lakhani SR, Simpson PT. 2008. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32: 773-783.
16. Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML. 2010. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120: 409-418.
17. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H. 2010. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17: 667-677.
18. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D. 2010, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer.
19. Foote FW, Stewart FW. 1941. Lobular carcinoma in situ: A rare form of mammary cancer. Am J Pathol 17: 491-496.
20. Gallardo A, Lerma E, Escuin D, Tibau A, Munoz J, Ojeda B, Barnadas A, Adrover E, Sanchez-Tejada L, Giner D, Ortiz-Martinez F, Peiro G. 2012. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106: 1367-1373.
21. Gottschalk AR, Doan A, Nakamura JL, Stokoe D, Haas-Kogan DA. 2005. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 63: 1221-1227.
22. Hanby AM. 2005. Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer 92: 613-617.
23. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. 2009. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69: 3625-3633.
24. Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME. 2011. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129: 635-643.
25. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. 2009. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-5059.
26. Kaufmann M, Morrow M, von Minckwitz G, Harris JR. 2011. Locoregional treatment of primary breast cancer: Consensus recommendations from an International Expert Panel. Cancer 116: 1184-1191.
27. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H. 2002. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 62: 6634-6638.
28. Li HF, Kim JS, Waldman T. 2009. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4: 43.
29. Maira SM. 2011. PI3K inhibitors for cancer treatment: Five years of preclinical and clinical research after BEZ235. Mol Cancer Ther 10: 2016.
30. Mandell JW. 2008. Immunohistochemical assessment of protein phosphorylation state: The dream and the reality. Histochem Cell Biol 130: 465-471.
31. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. 2007. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13: 408-414.
32. Matthews DJ, Gerritsen ME. 2010, Targeting Protein Kinases for Cancer Therapy. Hoboken, New Jersey: Wiley.
33. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. 2002. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198: 292-299.
34. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A. 2009. PIK3CA in breast carcinoma: A mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 18: 200-205.
35. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. 2010. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70: 5674-5678.
36. Mylonas I, Janni W, Friese K, Gerber B. 2004. Unexpected metastatic lobular carcinoma of the breast with intraabdominal spread and subsequent port-site metastasis after diagnostic laparoscopy for exclusion of ovarian cancer. Gynecol Oncol 95: 405-408.
37. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR. 2010. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16: 3670-3683.
38. O'Malley FP. 2010. Lobular neoplasia: Morphology, biological potential and management in core biopsies. Mod Pathol 23 ( Suppl 2): S14-S25.
39. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. 2005. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46: 685-693.
40. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO. 2008. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 44: 73-83.
41. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. 2005. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
42. Sarker D, Kristeleit R, Mazina KE, Ware JA, Yan Y, Dresser M, Derynck MK, DeBono J. 2009. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 27:( suppl); abstract 3538.
43. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. 2009. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
44. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. 2008. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
45. Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M. 2006. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25: 2950-2952.
46. Truin W, Voogd AC, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen RM. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol (in press). doi:10.1093/annonc/mds180.
47. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P, Rouesse J. 2006. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 17: 1228-1233.
48. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL. 2008. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150.
49. Whitehall V, Rickman C, Bond C, Ramsnes I, Greco S, Umapathy A, McKeone D, Faleiro R, Buttenshaw R, Worthley D, Nayler S, Zhao Z, Montgomery G, Mallitt K, Jass J, Matsubara N, Notohara K, Ishii T, Leggett B. 2012. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 131: 813-820.
50. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Borresen-Dale AL, Jeffrey SS. 2004. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15: 2523-2536.
51. Zhao L, Vogt PK. 2008. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105: 2652-2657.